Financhill
Sell
36

BDRX Quote, Financials, Valuation and Earnings

Last price:
$4.31
Seasonality move :
-20.94%
Day range:
$4.15 - $4.54
52-week range:
$3.50 - $74.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.08x
P/B ratio:
0.24x
Volume:
16K
Avg. volume:
57.9K
1-year change:
-91.22%
Market cap:
$2.6M
Revenue:
$474.1K
EPS (TTM):
-$74.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.97
ADAP
Adaptimmune Therapeutics PLC
$8.8M -$0.15 4199.24% -9.44% $2.27
AUTL
Autolus Therapeutics PLC
$3M -$0.24 -61.82% -46.14% $10.45
MREO
Mereo BioPharma Group PLC
$12.1M $0.01 1109.31% -69.36% $7.48
NCNA
NuCana PLC
-- -$0.09 -- -98.11% $64.50
TCBP
TC BioPharm (Holdings) PLC
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BDRX
Biodexa Pharmaceuticals PLC
$4.52 $17.97 $2.6M -- $0.00 0% 4.08x
ADAP
Adaptimmune Therapeutics PLC
$0.62 $2.27 $158.6M -- $0.00 0% 0.87x
AUTL
Autolus Therapeutics PLC
$2.36 $10.45 $628M -- $0.00 0% --
MREO
Mereo BioPharma Group PLC
$3.55 $7.48 $550.8M -- $0.00 0% --
NCNA
NuCana PLC
$1.13 $64.50 $4.4M -- $0.00 0% --
TCBP
TC BioPharm (Holdings) PLC
$0.40 -- $3.3M -- $0.25 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BDRX
Biodexa Pharmaceuticals PLC
-- 0.100 -- 1.20x
ADAP
Adaptimmune Therapeutics PLC
38.4% 4.431 20.51% 3.54x
AUTL
Autolus Therapeutics PLC
-- 3.664 -- 17.97x
MREO
Mereo BioPharma Group PLC
-- 0.058 -- --
NCNA
NuCana PLC
-- 1.546 -- --
TCBP
TC BioPharm (Holdings) PLC
-- -1.581 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
ADAP
Adaptimmune Therapeutics PLC
-- -$14.7M -55.22% -67.8% -38.33% -$54.9M
AUTL
Autolus Therapeutics PLC
-- -$67.7M -80.74% -80.74% -331.28% -$86.3M
MREO
Mereo BioPharma Group PLC
-- -$9.1M -- -- -- -$7.5M
NCNA
NuCana PLC
-- -$6.6M -- -- -- -$6.4M
TCBP
TC BioPharm (Holdings) PLC
-- -$2.6M -- -- -- -$3.5M

Biodexa Pharmaceuticals PLC vs. Competitors

  • Which has Higher Returns BDRX or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -43.07%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
  • What do Analysts Say About BDRX or ADAP?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 297.6%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.27 which suggests that it could grow by 265.59%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    4 2 0
  • Is BDRX or ADAP More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.460, which suggesting that the stock is 46.046% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.236, suggesting its more volatile than the S&P 500 by 123.631%.

  • Which is a Better Dividend Stock BDRX or ADAP?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or ADAP?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 4.08x versus 0.87x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    4.08x -- -- --
    ADAP
    Adaptimmune Therapeutics PLC
    0.87x -- $40.9M -$17.6M
  • Which has Higher Returns BDRX or AUTL?

    Autolus Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -522.15%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Autolus Therapeutics PLC's return on equity of -80.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    AUTL
    Autolus Therapeutics PLC
    -- -$0.31 $582M
  • What do Analysts Say About BDRX or AUTL?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 297.6%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 342.8%. Given that Autolus Therapeutics PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Autolus Therapeutics PLC is more attractive than Biodexa Pharmaceuticals PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    AUTL
    Autolus Therapeutics PLC
    8 0 0
  • Is BDRX or AUTL More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.460, which suggesting that the stock is 46.046% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.

  • Which is a Better Dividend Stock BDRX or AUTL?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or AUTL?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 4.08x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    4.08x -- -- --
    AUTL
    Autolus Therapeutics PLC
    -- -- $10.1M -$82.1M
  • Which has Higher Returns BDRX or MREO?

    Mereo BioPharma Group PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Mereo BioPharma Group PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    MREO
    Mereo BioPharma Group PLC
    -- -$0.10 --
  • What do Analysts Say About BDRX or MREO?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 297.6%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.48 which suggests that it could grow by 110.78%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    MREO
    Mereo BioPharma Group PLC
    6 0 0
  • Is BDRX or MREO More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.460, which suggesting that the stock is 46.046% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.911, suggesting its less volatile than the S&P 500 by 8.911%.

  • Which is a Better Dividend Stock BDRX or MREO?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or MREO?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than Mereo BioPharma Group PLC's net income of -$15M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 4.08x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    4.08x -- -- --
    MREO
    Mereo BioPharma Group PLC
    -- -- -- -$15M
  • Which has Higher Returns BDRX or NCNA?

    NuCana PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    NCNA
    NuCana PLC
    -- -$2.28 --
  • What do Analysts Say About BDRX or NCNA?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 297.6%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 5607.97%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    NCNA
    NuCana PLC
    1 2 0
  • Is BDRX or NCNA More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.460, which suggesting that the stock is 46.046% more volatile than S&P 500. In comparison NuCana PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.67%.

  • Which is a Better Dividend Stock BDRX or NCNA?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or NCNA?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than NuCana PLC's net income of -$5.9M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 4.08x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    4.08x -- -- --
    NCNA
    NuCana PLC
    -- -- -- -$5.9M
  • Which has Higher Returns BDRX or TCBP?

    TC BioPharm (Holdings) PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat TC BioPharm (Holdings) PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    TCBP
    TC BioPharm (Holdings) PLC
    -- -$5.07 --
  • What do Analysts Say About BDRX or TCBP?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 297.6%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 499.25%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Biodexa Pharmaceuticals PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    TCBP
    TC BioPharm (Holdings) PLC
    0 0 0
  • Is BDRX or TCBP More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.460, which suggesting that the stock is 46.046% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BDRX or TCBP?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or TCBP?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 4.08x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    4.08x -- -- --
    TCBP
    TC BioPharm (Holdings) PLC
    -- -- -- -$2.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

4 Top Dividend Stocks to Buy Now
4 Top Dividend Stocks to Buy Now

If you’re looking for steady income, dividend stocks are a…

Will Uber Stock Recover?
Will Uber Stock Recover?

Shares of Uber Technologies (NYSE:UBER) have had a rough few…

Is ARK Next Generation Internet ETF a Good Investment?
Is ARK Next Generation Internet ETF a Good Investment?

The ARK Next Generation Internet ETF looks like a pretty…

Stock Ideas

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
39
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
87
CEG alert for Jan 11

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
1
MCY alert for Jan 11

Mercury General [MCY] is down 19.87% over the past day.

Buy
84
ATZAF alert for Jan 11

Aritzia [ATZAF] is up 17.63% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock